Jeff Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses upcoming milestones in 2018 for his company, including plans to begin a program in Pompe disease. Spark is advancing research programs against cell targets in the retina, liver and central nervous system using adeno-associated viral (AAV) vectors. The vectors used in the company’s research programs have been engineered using Spark’s proprietary platform, selected through vigorous preclinical testing and validated in several clinical trials.